XTNT (Xtant Medical Holdings) EBIT: $7.1 Mil (TTM As of Mar. 2026)


XTNT Xtant Medical Holdings Inc XTNT
31 GF Score
Price $0.42
GF Value $0.62
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Xtant Medical Holdings EBIT?

Xtant Medical Holdings XTNT -1.95% 31 EBIT is $7.1 Mil as of Mar. 2026. GuruFocus rates XTNT with a GF Score™ of 31/100 and a GF Value™ of $0.62 (Possible Value Trap). The stock has 4 warning signs investors should review.

Xtant Medical Holdings's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-2.5 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $7.1 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Xtant Medical Holdings's annualized ROC % for the quarter that ended in Mar. 2026 was -20.42%. Xtant Medical Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -21.63%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Xtant Medical Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 11.42%.

Xtant Medical Holdings  (AMEX:XTNT) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Xtant Medical Holdings's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-11.692 * ( 1 - 0% )/( (62.622 + 51.903)/ 2 )
=-11.692/57.2625
=-20.42 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=94.145 - 14.47 - ( 17.053 - max(0, 29.484 - 78.245+17.053))
=62.622

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=78 - 13.96 - ( 12.137 - max(0, 18.773 - 62.621+12.137))
=51.903

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Xtant Medical Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-9.852/( ( (9.394 + max(36.26, 0)) + (8.899 + max(36.524, 0)) )/ 2 )
=-9.852/( ( 45.654 + 45.423 )/ 2 )
=-9.852/45.5385
=-21.63 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(17.803 + 30.263 + 2.664) - (14.47 + 0 + 0)
=36.26

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(17.179 + 31.881 + 1.424) - (13.96 + 0 + 0)
=36.524

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Xtant Medical Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=7.131/62.434
=11.42 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xtant Medical Holdings EBIT Related Terms

Xtant Medical Holdings EBIT Historical Data

* Premium members only.

The historical data trend for Xtant Medical Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xtant Medical Holdings EBIT Chart

Xtant Medical Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.85 -6.72 1.90 -12.10 10.67

Xtant Medical Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.08 4.81 2.47 2.32 -2.46

XTNT vs MDAI, QTI, POSC: EBIT Comparison

For the Medical Devices subindustry, Xtant Medical Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Xtant Medical Holdings EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xtant Medical Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Xtant Medical Holdings's EV-to-EBIT falls into.


XTNT
31GF Score
Xtant Medical Holdings Inc XTNT
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xtant Medical Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $7.1 Mil mean?
Xtant Medical Holdings (XTNT) has a EBIT of $7.1 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Xtant Medical Holdings.
Is Xtant Medical Holdings' EBIT too high?
Xtant Medical Holdings' current EBIT is $7.1 Mil. Overall, Xtant Medical Holdings has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Xtant Medical Holdings' EBIT compare to MDAI and QTI?
Xtant Medical Holdings' EBIT of $7.1 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Xtant Medical Holdings. Xtant Medical Holdings's current EBIT is $7.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xtant Medical Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xtant Medical Holdings (XTNT) is currently considered Possible Value Trap. The stock's GF Value™ is $0.62, compared to a current price of $0.42 — trading 32% below its estimated fair value. The current EBIT is $7.1 Mil. Xtant Medical Holdings' overall GF Score™ is 31/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Xtant Medical Holdings (XTNT), the current EBIT is $7.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xtant Medical Holdings (XTNT) Overvalued in 2026?

Based on GuruFocus' analysis, Xtant Medical Holdings stock appears to be undervalued. The current stock price of $0.42 is trading 32% below its estimated GF Value™ of $0.62. GuruFocus considers Xtant Medical Holdings to be Possible Value Trap.

Key valuation signals for XTNT:

  • EBIT: $7.1 Mil
  • GF Value™: $0.62 vs. price of $0.42 (32% below fair value)
  • GF Score™: 31/100 with 4 warning signs

No single metric tells the full story. See the XTNT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xtant Medical Holdings Business Description

Address 664 Cruiser Lane, Belgrade, MT, USA, 59714
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
31GF Score

Get the complete analysis for XTNT

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42
Price
$0.62
GF Value